Global Cancer Pain Market Insights, Forecast to 2025
Published On: September 2018
 
Report ID:307017
 
Publisher: QY Research
 
 
Pages: 118




Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostic procedures or from skin, nerve, and the other changes caused by a hormone imbalance or immune response.

The report, states that opioids will continue to dominate as a breakthrough cancer pain treatment, mostly due to available generics and physician familiarity.

In 2017, the global Cancer Pain market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Cancer Pain market based on company, product type, application and key regions.

This report studies the global market size of Cancer Pain in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer Pain in these regions.

This research report categorizes the global Cancer Pain market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

The various contributors involved in the value chain of Cancer Pain include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Cancer Pain include

BioDelivery Science

ProStrakan Group

Teva pharmaceuticals

Eli-Lilly

Grunenthal Group

GW Pharmaceuticals

Johnson&Johnson

Meda Pharmaceuticals

Orexo

Sanofi

WEX Pharmaceuticals

Market Size Split by Type

Opioids

Non-Steroidal Anti-Inflammatory Drugs

Others

Market Size Split by Application

Paracetamol Treatment-Related Immunotherapy

Radiotherapy

Chemotherapy

Hormone Therapy

Market size split by Region

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

South Korea

Australia

Indonesia

Singapore

Malaysia

Philippines

Thailand

Vietnam

Europe

Germany

France

UK

Italy

Spain

Russia

Central & South America

Brazil

Rest of Central & South America

Middle East & Africa

GCC Countries

Turkey

Egypt

South Africa

The study objectives of this report are:

To study and analyze the global Cancer Pain market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.

To understand the structure of Cancer Pain market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Cancer Pain manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Cancer Pain with respect to individual growth trends, future prospects, and their contribution to the total market.

To project the value and volume of Cancer Pain submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Cancer Pain are as follows:

History Year: 2013-2017

Base Year: 2017

Estimated Year: 2018

Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cancer Pain market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage

1.1 Cancer Pain Product

1.2 Key Market Segments

1.3 Key Manufacturers Covered

1.4 Market by Type

1.4.1 Global Cancer Pain Market Size Growth Rate by Type

1.4.2 Opioids

1.4.3 Non-Steroidal Anti-Inflammatory Drugs

1.4.4 Others

1.5 Market by Application

1.5.1 Global Cancer Pain Market Size Growth Rate by Application

1.5.2 Paracetamol Treatment-Related Immunotherapy

1.5.3 Radiotherapy

1.5.4 Chemotherapy

1.5.5 Hormone Therapy

1.6 Study Objectives

1.7 Years Considered

2 Executive Summary

2.1 Global Cancer Pain Market Size

2.1.1 Global Cancer Pain Revenue 2016-2025

2.1.2 Global Cancer Pain Sales 2016-2025

2.2 Cancer Pain Growth Rate by Regions

2.2.1 Global Cancer Pain Sales by Regions

2.2.2 Global Cancer Pain Revenue by Regions

3 Breakdown Data by Manufacturers

3.1 Cancer Pain Sales by Manufacturers

3.1.1 Cancer Pain Sales by Manufacturers

3.1.2 Cancer Pain Sales Market Share by Manufacturers

3.1.3 Global Cancer Pain Market Concentration Ratio (CR5 and HHI)

3.2 Cancer Pain Revenue by Manufacturers

3.2.1 Cancer Pain Revenue by Manufacturers (2016-2018)

3.2.2 Cancer Pain Revenue Share by Manufacturers (2016-2018)

3.3 Cancer Pain Price by Manufacturers

3.4 Cancer Pain Manufacturing Base Distribution, Product Types

3.4.1 Cancer Pain Manufacturers Manufacturing Base Distribution, Headquarters

3.4.2 Manufacturers Cancer Pain Product Category

3.4.3 Date of International Manufacturers Enter into Cancer Pain Market

3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type

4.1 Global Cancer Pain Sales by Type

4.2 Global Cancer Pain Revenue by Type

4.3 Cancer Pain Price by Type

5 Breakdown Data by Application

5.1 Overview

5.2 Global Cancer Pain Breakdown Data by Application

6 North America

6.1 North America Cancer Pain by Countries

6.1.1 North America Cancer Pain Sales by Countries

6.1.2 North America Cancer Pain Revenue by Countries

6.1.3 United States

6.1.4 Canada

6.1.5 Mexico

6.2 North America Cancer Pain by Type

6.3 North America Cancer Pain by Application

6.4 North America Cancer Pain by Company

7 Europe

7.1 Europe Cancer Pain by Countries

7.1.1 Europe Cancer Pain Sales by Countries

7.1.2 Europe Cancer Pain Revenue by Countries

7.1.3 Germany

7.1.4 France

7.1.5 UK

7.1.6 Italy

7.1.7 Russia

7.2 Europe Cancer Pain by Type

7.3 Europe Cancer Pain by Application

7.4 Europe Cancer Pain by Company

8 Asia Pacific

8.1 Asia Pacific Cancer Pain by Countries

8.1.1 Asia Pacific Cancer Pain Sales by Countries

8.1.2 Asia Pacific Cancer Pain Revenue by Countries

8.1.3 China

8.1.4 Japan

8.1.5 Korea

8.1.6 India

8.1.7 Australia

8.1.8 Indonesia

8.1.9 Malaysia

8.1.10 Philippines

8.1.11 Thailand

8.1.12 Vietnam

8.1.13 Singapore

8.2 Asia Pacific Cancer Pain by Type

8.3 Asia Pacific Cancer Pain by Application

8.4 Asia Pacific Cancer Pain by Company

9 Central & South America

9.1 Central & South America Cancer Pain by Countries

9.1.1 Central & South America Cancer Pain Sales by Countries

9.1.2 Central & South America Cancer Pain Revenue by Countries

9.1.3 Brazil

9.2 Central & South America Cancer Pain by Type

9.3 Central & South America Cancer Pain by Application

9.4 Central & South America Cancer Pain by Company

10 Middle East and Africa

10.1 Middle East and Africa Cancer Pain by Countries

10.1.1 Middle East and Africa Cancer Pain Sales by Countries

10.1.2 Middle East and Africa Cancer Pain Revenue by Countries

10.1.3 GCC Countries

10.1.4 Turkey

10.1.5 Egypt

10.1.6 South Africa

10.2 Middle East and Africa Cancer Pain by Type

10.3 Middle East and Africa Cancer Pain by Application

10.4 Middle East and Africa Cancer Pain by Company

11 Company Profiles

11.1 BioDelivery Science

11.1.1 BioDelivery Science Company Details

11.1.2 Company Description

11.1.3 Sales, Revenue and Gross Margin of Cancer Pain

11.1.4 Cancer Pain Product Description

11.1.5 Recent Development

11.2 ProStrakan Group

11.2.1 ProStrakan Group Company Details

11.2.2 Company Description

11.2.3 Sales, Revenue and Gross Margin of Cancer Pain

11.2.4 Cancer Pain Product Description

11.2.5 Recent Development

11.3 Teva pharmaceuticals

11.3.1 Teva pharmaceuticals Company Details

11.3.2 Company Description

11.3.3 Sales, Revenue and Gross Margin of Cancer Pain

11.3.4 Cancer Pain Product Description

11.3.5 Recent Development

11.4 Eli-Lilly

11.4.1 Eli-Lilly Company Details

11.4.2 Company Description

11.4.3 Sales, Revenue and Gross Margin of Cancer Pain

11.4.4 Cancer Pain Product Description

11.4.5 Recent Development

11.5 Grunenthal Group

11.5.1 Grunenthal Group Company Details

11.5.2 Company Description

11.5.3 Sales, Revenue and Gross Margin of Cancer Pain

11.5.4 Cancer Pain Product Description

11.5.5 Recent Development

11.6 GW Pharmaceuticals

11.6.1 GW Pharmaceuticals Company Details

11.6.2 Company Description

11.6.3 Sales, Revenue and Gross Margin of Cancer Pain

11.6.4 Cancer Pain Product Description

11.6.5 Recent Development

11.7 Johnson&Johnson

11.7.1 Johnson&Johnson Company Details

11.7.2 Company Description

11.7.3 Sales, Revenue and Gross Margin of Cancer Pain

11.7.4 Cancer Pain Product Description

11.7.5 Recent Development

11.8 Meda Pharmaceuticals

11.8.1 Meda Pharmaceuticals Company Details

11.8.2 Company Description

11.8.3 Sales, Revenue and Gross Margin of Cancer Pain

11.8.4 Cancer Pain Product Description

11.8.5 Recent Development

11.9 Orexo

11.9.1 Orexo Company Details

11.9.2 Company Description

11.9.3 Sales, Revenue and Gross Margin of Cancer Pain

11.9.4 Cancer Pain Product Description

11.9.5 Recent Development

11.10 Sanofi

11.10.1 Sanofi Company Details

11.10.2 Company Description

11.10.3 Sales, Revenue and Gross Margin of Cancer Pain

11.10.4 Cancer Pain Product Description

11.10.5 Recent Development

11.11 WEX Pharmaceuticals

12 Market Opportunities, Challenges, Risks and Influences Factors Analysis

12.1 Market Opportunities and Drivers

12.2 Market Challenges

12.3 Market Risks/Restraints

12.4 Key World Economic Indicators

13 Value Chain and Sales Channels Analysis

13.1 Value Chain Analysis

13.1.1 Typical Suppliers of Key Cancer Pain Raw Material

13.1.2 Cancer Pain Customers

13.2 Sales Channels Analysis

13.2.1 Sales Channels Analysis

13.2.2 Distributors

14 Research Findings and Conclusion

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

15.3 Disclaimer






Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
   Our Clients
  • \
   Payment Mode



For More Information

   For More Information

If you have any query? Please contact us

sales@fiormarkets.com
+1-201-465-4211


Copyright © 2019 Fior Market Research LLP, All Rights Reserved.